Press Releases / Notices

Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, President: Mr. Shigenobu Maekawa) and Labopharm Europe Limited (Headquarters: Ireland Dublin, Managing Director: Mr. Anthony Playle), which is wholly owned subsidiary of Labopharm Inc, (Headquarters: Canada Quebec, President and CEO: Mr. James R. Howard-Tripp) announced that they have concluded a license agreement for once-daily tramadol sustained release tablet with respect to its exclusive development, marketing and distributing right in Japan.

Labopharm’s once-daily tramadol sustained release tablet, a unique once-daily oral formulation to which its own lead technology platform, Contramid®, is applied, has already been launched in 17 countries including the U.S., Canada and European countries for the treatment of patients who are suffering moderate to moderately severe pain.

We have already launched the tramadol injection product, Tramal Injection 100, in Japan. And also, we have submitted the New Drug Application for Tramadol immediate release capsules (Development Code: NS-315). It is our sincere hope that this Labopharm’s tramadol product which differs from our other tramadol products will strengthen our tramadol product lineup that results in fulfilling the patient’s needs for the treatment of pain.

About Labopharm Inc

【Locations】Canada Quebec
【Established】1994
【Business lines】Optimizing the performance of existing small molecule drugs 　　using its proprietary controlled-release technologies
【Sales】CAD22mil (2008)
【Employees】124